Literature DB >> 16231957

Detecting treatment emergent adverse events in clinical trials : a comparison of spontaneously reported and solicited collection methods.

Joachim F Wernicke1, Douglas Faries, Denái Milton, Karen Weyrauch.   

Abstract

BACKGROUND: The collection of adverse event data is an important component of clinical trials, but it is not clear whether solicited or unsolicited collection methods are better at distinguishing drug effects from the effects of placebo. The objective of this analysis is to compare the reporting rates and the ability to detect drug-placebo differences with spontaneous versus solicited adverse event collection methods.
METHODS: Adverse events were collected by spontaneous (unsolicited) reporting and by structured questionnaires in three randomised, double-blind clinical trials. For both spontaneous and solicited adverse event collection methods, a drug/placebo (D/P) reporting ratio was computed by dividing the reporting rate for the experimental drug by the reporting rate for placebo for each adverse event. An index (Sp-So index) was calculated by dividing the spontaneous D/P ratio by the solicited D/P ratio. A number >1.0 indicates that the spontaneous adverse event collection method is more effective in distinguishing the drug from placebo and a number <1.0 suggests that the solicited adverse event collection method is more effective in distinguishing the drug from placebo.
RESULTS: Reporting rates were greater when events were solicited than when the spontaneous reporting approach was used. The Sp-So index was >1.0 for 22 of the 29 (75.9%) events examined, suggesting that spontaneous collection of adverse events is more effective in distinguishing drug effect from placebo than the solicited approach. However, more statistically significant differences between drug and placebo were detected by the solicited method (nine events) than the spontaneous method (five events). This is due, in part, to the fact that differences in the percentages of adverse events between drug and placebo (rather than ratios of event rates) were more often greater when the solicited approach was used.
CONCLUSIONS: As expected, adverse events collected by solicitation leads to higher reporting rates. However, it is not clear that solicitation of events leads to greater ability to detect drug-placebo differences. By using a ratio to assess drug-placebo differences, spontaneous reporting provided larger drug-placebo differences more often than solicitation.

Entities:  

Mesh:

Year:  2005        PMID: 16231957     DOI: 10.2165/00002018-200528110-00006

Source DB:  PubMed          Journal:  Drug Saf        ISSN: 0114-5916            Impact factor:   5.606


  6 in total

Review 1.  The medical dictionary for regulatory activities (MedDRA).

Authors:  E G Brown; L Wood; S Wood
Journal:  Drug Saf       Date:  1999-02       Impact factor: 5.606

2.  General versus specific inquiry with SAFTEE.

Authors:  J Levine; N R Schooler
Journal:  J Clin Psychopharmacol       Date:  1992-12       Impact factor: 3.153

3.  General versus systematic inquiry about emergent clinical events with SAFTEE: implications for clinical research.

Authors:  J G Rabkin; J S Markowitz; K Ocepek-Welikson; S S Wager
Journal:  J Clin Psychopharmacol       Date:  1992-02       Impact factor: 3.153

4.  Side effects of methylphenidate in children with attention deficit hyperactivity disorder: a systemic, placebo-controlled evaluation.

Authors:  R A Barkley; M B McMurray; C S Edelbrock; K Robbins
Journal:  Pediatrics       Date:  1990-08       Impact factor: 7.124

5.  Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study.

Authors:  D Michelson; D Faries; J Wernicke; D Kelsey; K Kendrick; F R Sallee; T Spencer
Journal:  Pediatrics       Date:  2001-11       Impact factor: 7.124

6.  Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies.

Authors:  David Michelson; Lenard Adler; Thomas Spencer; Frederick W Reimherr; Scott A West; Albert J Allen; Douglas Kelsey; Joachim Wernicke; Anthony Dietrich; Denái Milton
Journal:  Biol Psychiatry       Date:  2003-01-15       Impact factor: 13.382

  6 in total
  15 in total

Review 1.  Cause or Effect? Selective Serotonin Reuptake Inhibitors and Falls in Older Adults: A Systematic Review.

Authors:  Marie Anne Gebara; Kim L Lipsey; Jordan F Karp; Maureen C Nash; Andrea Iaboni; Eric J Lenze
Journal:  Am J Geriatr Psychiatry       Date:  2014-11-25       Impact factor: 4.105

Review 2.  Strategies for dealing with fraud in clinical trials.

Authors:  Jay Herson
Journal:  Int J Clin Oncol       Date:  2015-07-21       Impact factor: 3.402

Review 3.  Allergen Immunotherapy Clinical Trial Outcomes and Design: Working Toward Harmonization of Methods and Principles.

Authors:  Harold S Nelson; Moises A Calderon; David I Bernstein; Thomas B Casale; Stephen R Durham; Jens S Andersen; Robert Esch; Linda S Cox; Hendrik Nolte
Journal:  Curr Allergy Asthma Rep       Date:  2017-03       Impact factor: 4.806

4.  Effect of an Outreach Programme on Vandetanib Safety in Medullary Thyroid Cancer.

Authors:  Lars Bastholt; Michael C Kreissl; Dagmar Führer; Ana L Maia; Laura D Locati; Léa Maciel; Yi Wu; Kevin N Heller; Alan Webster; Rossella Elisei
Journal:  Eur Thyroid J       Date:  2016-09-10

5.  Growth hormone treatment does not affect incidences of middle ear disease or hearing loss in infants and toddlers with Turner syndrome.

Authors:  Marsha L Davenport; Jackson Roush; Chunhua Liu; Anthony J Zagar; Erica Eugster; Sharon Travers; Patricia Y Fechner; Charmian A Quigley
Journal:  Horm Res Paediatr       Date:  2010-04-27       Impact factor: 2.852

6.  Improving reporting of adverse drug reactions: Systematic review.

Authors:  Mariam Molokhia; Shivani Tanna; Derek Bell
Journal:  Clin Epidemiol       Date:  2009-08-09       Impact factor: 4.790

7.  Assessment of falls in older patients treated with duloxetine: a secondary analysis of a 24-week randomized, placebo-controlled trial.

Authors:  J Craig Nelson; Tina M M Oakes; Peng Liu; Jonna Ahl; Mark E Bangs; Joel Raskin; David G Perahia; Michael J Robinson
Journal:  Prim Care Companion CNS Disord       Date:  2012-01-03

Review 8.  Eliciting adverse effects data from participants in clinical trials.

Authors:  Elizabeth N Allen; Clare Ir Chandler; Nyaradzo Mandimika; Cordelia Leisegang; Karen Barnes
Journal:  Cochrane Database Syst Rev       Date:  2018-01-16

9.  How experiences become data: the process of eliciting adverse event, medical history and concomitant medication reports in antimalarial and antiretroviral interaction trials.

Authors:  Elizabeth N Allen; Adiel K Mushi; Isolide S Massawe; Lasse S Vestergaard; Martha Lemnge; Sarah G Staedke; Ushma Mehta; Karen I Barnes; Clare I R Chandler
Journal:  BMC Med Res Methodol       Date:  2013-11-14       Impact factor: 4.615

10.  Evaluating harm associated with anti-malarial drugs: a survey of methods used by clinical researchers to elicit, assess and record participant-reported adverse events and related data.

Authors:  Elizabeth N Allen; Clare I R Chandler; Nyaradzo Mandimika; Cheryl Pace; Ushma Mehta; Karen I Barnes
Journal:  Malar J       Date:  2013-09-16       Impact factor: 2.979

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.